FR941222-2-00058 FR941222-2-00050 Prospective Grant of Exclusive License: Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application SN 07/945,515 entitled ``Neutralizing Monoclonal Antibodies for Respiratory Syncytial Virus'' and related foreign patent applications to SmithKline Beecham Corporation, of Philadelphia, Pennsylvania. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the fields of treatment and prevention of RSV infection in humans. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The patent application describes human monoclonal antibodies which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B. These monoclonal antibodies may be used alone or in mixtures to treat or prevent RSV infection. Cell lines secreting the monoclonals are also described. ADDRESSES: Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Robert Benson, Patent Advisor, Office of Technology Transfer, National Institutes of Health, 6011 Executive Blvd., Box 13, Rockville, MD 20852. Telephone: (301) 496&hyph;7056, X267; Facsimile: (301) 402&hyph;0220. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH within sixty (60) days of this notice will be considered. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application. Dated: December 12, 1994. Barbara M. McGarey, Deputy Director, Office of Technology Transfer. [FR Doc. 94&hyph;31394 Filed 12&hyph;21&hyph;94; 8:45 am] BILLING CODE 4140&hyph;01&hyph;P
